2 terminated, 1 no longer available, 1 withdrawn. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Terminated 1 |
Follow PRO051: new trials by email Literature Review of PRO051 trials Research Report on PRO051
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drisapersen Duchenne Muscular Dystrophy (DMD) Treatment Protocol Drisapersen - Muscular Dystrophies | Phase 3 | Withdrawn | GlaxoSmithKline | 2014-01-01 | 2014-03-24 | |
| A Study of the Safety, Tolerability & Efficacy of Long-term Administration of Drisapersen in US & Canadian Subjects Drisapersen - Muscular Dystrophies | Phase 3 | Terminated | BioMarin Pharmaceutical | 53 | 2013-05-01 | 2018-06-14 |
| A Phase I/II, Open Label, Escalating Dose, Pilot Study to Assess Effect, Safety, Tolerability and PK of Multiple SC Doses of Drisapersen in Patients With Duchenne Muscular Dystrophy and to Assess the Potential for IV Dosing as an Alternative Route of Administration Drisapersen - Muscular Dystrophies | Phase 2 | Terminated | BioMarin Pharmaceutical | 12 | 2008-03-01 | 2016-11-07 |
| Extension Study of Drisapersen in DMD Subjects Drisapersen - Duchenne Muscular Dystrophy | No longer available | BioMarin Pharmaceutical | 2018-01-24 |
Muscular Dystrophies (3) · Muscular Dystrophy, Duchenne (3)
BioMarin Pharmaceutical (3) · GlaxoSmithKline (1)
United States (2) · Argentina (1) · Australia (1) · Belgium (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1) · Poland (1)
Derry Ridgway, MD (1) · N Goemans, Dr. (1)